Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AbbVie, abolished, abroad, actuarial, AmeriSourceBergen, Amsterdam, Arixtra, Biopharm, Biopharma, campaign, Carlo, cautionary, Chatillon, CMA, conspiracy, contemplated, contraceptive, core, deal, discourage, divert, expeditiously, Explanatory, facilitating, Famy, female, fine, fined, frame, half, hardware, incomplete, insert, Instruction, inversion, INVERTED, Katsuyama, LAMA, lessen, merger, Monte, Moon, Onco, path, PMDL, preserve, processed, promised, PSU, random, recast, Reclassification, reconstruct, regenerative, replacement, restrain, route, SAR, seat, simulation, SSO, strongly, supersede, Task, Theravance, thereunder
Removed:
accrual, acting, Advair, AG, AGs, Alabama, Alaska, ameliorate, American, California, capability, China, cooperate, cooperating, county, declined, defrauded, Delaware, discontinuation, dispositive, East, EMEA, fastest, Florida, Fluticasone, furnish, gap, generating, Hawaii, hydrochloride, Idaho, incorporating, incumbent, inhaled, injunction, injunctive, inquiry, insolvency, intervene, Iowa, Justice, Kentucky, Labour, lender, levalbuterol, litigated, Louisiana, mentioned, Middle, Mississippi, Missouri, municipal, nationwide, Oklahoma, outpaced, overpay, overpayment, owed, Pacific, par, PPA, prejudice, prepare, pretrial, principle, Propionate, purported, recourse, rehabilitation, reinstated, Salmeterol, Seretide, spread, surcharge, swapped, takeover, taxpayer, translating, Trust, UDL, unaffiliated, underlie, USP, Utah, Wisconsin, withdrawing, zone
Filing tables
Filing exhibits
- 10-K Annual report
- 10.57 Exhibit 10.57
- 10.58 Exhibit 10.58
- 10.59 Exhibit 10.59
- 10.60 Exhibit 10.60
- 10.61 Exhibit 10.61
- 10.62 Exhibit 10.62
- 10.63 Exhibit 10.63
- 10.41 Exhibit 10.41(B)
- 10.42 Exhibit 10.42(B)
- 10.56 Exhibit 10.56(A)
- 10.56 Exhibit 10.56(B)
- 12.1 Exhibit 12.1
- 21.1 Exhibit 21.1
- 23 Exhibit 23
- 31.1 Exhibit 31.1
- 31.2 Exhibit 31.2
- 32 Exhibit 32
- Download Excel data file
- View Excel data file
Related press release
Mylan similar filings
Filing view
External links
EXHIBIT 32
CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND
PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Form 10-K of Mylan Inc. (the “Company”) for the year ended December 31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, in the capacities and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: March 2, 2015
/s/ Heather Bresch | |
Heather Bresch Chief Executive Officer (Principal Executive Officer) |
/s/ John D. Sheehan | |
John D. Sheehan Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) |
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
The foregoing certification is being furnished in accordance with Securities and Exchange Commission Release No. 34-47551 and shall not be considered filed as part of the Form 10-K.